HRP20191895T4 - Adam6 miševi - Google Patents

Adam6 miševi Download PDF

Info

Publication number
HRP20191895T4
HRP20191895T4 HRP20191895TT HRP20191895T HRP20191895T4 HR P20191895 T4 HRP20191895 T4 HR P20191895T4 HR P20191895T T HRP20191895T T HR P20191895TT HR P20191895 T HRP20191895 T HR P20191895T HR P20191895 T4 HRP20191895 T4 HR P20191895T4
Authority
HR
Croatia
Prior art keywords
mouse
modification
heavy chain
immunoglobulin heavy
murine
Prior art date
Application number
HRP20191895TT
Other languages
English (en)
Croatian (hr)
Inventor
Lynn Macdonald
Sean Stevens
Andrew J. Murphy
Original Assignee
Regeneron Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45998616&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20191895(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharmaceuticals, Inc. filed Critical Regeneron Pharmaceuticals, Inc.
Publication of HRP20191895T1 publication Critical patent/HRP20191895T1/hr
Publication of HRP20191895T4 publication Critical patent/HRP20191895T4/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating devices
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating devices
    • B60H1/22—Heating, cooling or ventilating devices the heat source being other than the propulsion plant
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating devices
    • B60H1/32—Cooling devices
    • B60H1/3204—Cooling devices using compression
    • B60H1/3228—Cooling devices using compression characterised by refrigerant circuit configurations
    • B60H1/32281—Cooling devices using compression characterised by refrigerant circuit configurations comprising a single secondary circuit, e.g. at evaporator or condenser side
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating devices
    • B60H1/32—Cooling devices
    • B60H1/3204—Cooling devices using compression
    • B60H1/323—Cooling devices using compression characterised by comprising auxiliary or multiple systems, e.g. plurality of evaporators, or by involving auxiliary cooling devices
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating devices
    • B60H1/00642—Control systems or circuits; Control members or indication devices for heating, cooling or ventilating devices
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating devices
    • B60H1/00007—Combined heating, ventilating, or cooling devices
    • B60H1/00021—Air flow details of HVAC devices
    • B60H2001/00185—Distribution of conditionned air
    • B60H2001/00192—Distribution of conditionned air to left and right part of passenger compartment
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating devices
    • B60H1/00007—Combined heating, ventilating, or cooling devices
    • B60H1/00021—Air flow details of HVAC devices
    • B60H2001/00185—Distribution of conditionned air
    • B60H2001/002—Distribution of conditionned air to front and rear part of passenger compartment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/20—Pseudochromosomes, minichrosomosomes
    • C12N2800/204—Pseudochromosomes, minichrosomosomes of bacterial origin, e.g. BAC
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Environmental Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Animal Husbandry (AREA)
  • Thermal Sciences (AREA)
  • Mechanical Engineering (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
HRP20191895TT 2011-02-25 2012-02-24 Adam6 miševi HRP20191895T4 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161446895P 2011-02-25 2011-02-25
US201161497650P 2011-06-16 2011-06-16
US201261595200P 2012-02-06 2012-02-06
EP12192727.1A EP2578688B2 (en) 2011-02-25 2012-02-24 ADAM6 mice

Publications (2)

Publication Number Publication Date
HRP20191895T1 HRP20191895T1 (hr) 2020-01-10
HRP20191895T4 true HRP20191895T4 (hr) 2023-05-12

Family

ID=45998616

Family Applications (5)

Application Number Title Priority Date Filing Date
HRP20191895TT HRP20191895T4 (hr) 2011-02-25 2012-02-24 Adam6 miševi
HRP20150262AT HRP20150262T1 (hr) 2011-02-25 2012-02-24 Miševi sa adam6
HRP20230526TT HRP20230526T1 (hr) 2011-02-25 2012-02-24 Adam6 miševi
HRP20192311TT HRP20192311T4 (hr) 2011-02-25 2012-02-24 Adam6 miševi
HRP20200294TT HRP20200294T1 (hr) 2011-02-25 2020-02-21 Miševi s adam6

Family Applications After (4)

Application Number Title Priority Date Filing Date
HRP20150262AT HRP20150262T1 (hr) 2011-02-25 2012-02-24 Miševi sa adam6
HRP20230526TT HRP20230526T1 (hr) 2011-02-25 2012-02-24 Adam6 miševi
HRP20192311TT HRP20192311T4 (hr) 2011-02-25 2012-02-24 Adam6 miševi
HRP20200294TT HRP20200294T1 (hr) 2011-02-25 2020-02-21 Miševi s adam6

Country Status (31)

Country Link
US (12) US8642835B2 (https=)
EP (7) EP2738258B2 (https=)
JP (8) JP2014507137A (https=)
KR (1) KR101387377B1 (https=)
CN (2) CN103429746B (https=)
AU (6) AU2012243291B2 (https=)
BR (1) BR112013021771B1 (https=)
CA (1) CA2820824A1 (https=)
CY (5) CY1116301T1 (https=)
DE (5) DE12192727T1 (https=)
DK (6) DK2578688T4 (https=)
ES (6) ES2748832T5 (https=)
FI (3) FI2738258T4 (https=)
HR (5) HRP20191895T4 (https=)
HU (5) HUE047687T2 (https=)
IL (4) IL226727A (https=)
IN (1) IN2013CN07629A (https=)
LT (4) LT2578688T (https=)
ME (3) ME02106B (https=)
MX (3) MX375115B (https=)
MY (1) MY172713A (https=)
NZ (3) NZ813867A (https=)
PL (5) PL2738259T3 (https=)
PT (5) PT2550363E (https=)
RS (5) RS59661B2 (https=)
RU (2) RU2722373C2 (https=)
SG (4) SG10201405135RA (https=)
SI (5) SI2578688T2 (https=)
SM (5) SMT202300173T1 (https=)
WO (1) WO2012141798A1 (https=)
ZA (1) ZA201305998B (https=)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20050144655A1 (en) 2000-10-31 2005-06-30 Economides Aris N. Methods of modifying eukaryotic cells
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
NZ537277A (en) 2002-07-18 2008-04-30 Crucell Holland Bv Recombinant production of mixtures of antibodies
ES2408582T3 (es) 2003-05-30 2013-06-21 Merus B.V. Biblioteca de Fab para la preparación de una mezcla de anticuerpos
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
SI2311874T1 (sl) 2004-07-22 2017-12-29 Erasmus University Medical Center Rotterdam Department of Cell Biology and Genetics Vezavne molekule
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
BR112012000536A2 (pt) * 2009-07-08 2020-08-11 Kymab Limited métodos para produção de anticorpo ou cadeia leve ou pesada de anticorpo específico para um antígeno desejado, para produção de anticorpo ou cadeia de anticorpo e seu uso, composição farmacêutica e derivado de anticorpo quimérico
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
SI2501817T2 (sl) 2010-02-08 2021-09-30 Regeneron Pharmaceuticals, Inc. Miš z navadno lahko verigo
SG10201912639SA (en) 2010-08-02 2020-02-27 Regeneron Pharma Mice that make binding proteins comprising vl domains
RU2722373C2 (ru) 2011-02-25 2020-05-29 Редженерон Фармасьютикалс, Инк. Мыши adam6
EP2739300B1 (en) 2011-07-05 2019-06-19 Duke University N-terminal deleted gp120 immunogens
RS59728B1 (sr) * 2011-08-05 2020-02-28 Regeneron Pharma Humanizovani miševi univerzalnog lakog lanca
WO2013041845A2 (en) 2011-09-19 2013-03-28 Kymab Limited Animals, repertoires & methods
BR112014006394A2 (pt) 2011-09-19 2017-03-28 Kymab Ltd manipulação de diversidade genética de imunoglobulina e terapêuticos multi-anticorpos
WO2013045916A1 (en) 2011-09-26 2013-04-04 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
CA2850745C (en) 2011-10-03 2022-12-13 Duke University Vaccine
KR20160098514A (ko) 2011-10-17 2016-08-18 리제너론 파아마슈티컬스, 인크. 제한된 면역글로불린 중쇄 마우스
GB201122047D0 (en) * 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
US20180295821A1 (en) * 2011-12-02 2018-10-18 Kymab Limited Transgenic Animals
RU2664181C2 (ru) 2011-12-20 2018-08-15 Регенерон Фармасьютикалз, Инк. Мыши с гуманизированной легкой цепью
RS62023B1 (sr) * 2012-02-01 2021-07-30 Regeneron Pharma Humanizovani glodari koji eksprimiraju teške lance koji sadrže vl domene
MX2014011047A (es) 2012-03-16 2015-04-08 Regeneron Pharma Ratones que producen proteinas de union a un antigeno con caracteristicas de union dependientes del ph.
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
SG10201700360VA (en) 2012-03-16 2017-03-30 Regeneron Pharma Non-human animals expressing ph-sensitive immunoglobulin sequences
KR102228296B1 (ko) 2012-03-16 2021-03-17 리제너론 파마슈티칼스 인코포레이티드 히스티딘 공학처리된 경쇄 항체 및 그것을 생성하기 위한 유전자 변형된 비-사람 동물
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
SI2838917T1 (sl) 2012-04-20 2019-11-29 Merus Nv Postopki in sredstva za produkcijo heterodimernih IG-podobnih molekul
PT3597037T (pt) 2012-06-12 2021-06-01 Regeneron Pharma Animais não humanos humanizados com lócus de cadeia pesada de imunoglobulina restrito
KR20150115775A (ko) 2013-02-06 2015-10-14 리제너론 파마슈티칼스 인코포레이티드 인간화된 동물을 이용한 b 세포 계통 기반의 면역원 설계
EP2840892B1 (en) 2013-02-20 2018-04-18 Regeneron Pharmaceuticals, Inc. Non-human animals with modified immunoglobulin heavy chain sequences
US9980470B2 (en) * 2013-03-14 2018-05-29 Erasmus University Medical Center Antibody production
US10993420B2 (en) 2013-03-15 2021-05-04 Erasmus University Medical Center Production of heavy chain only antibodies in transgenic mammals
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
DE112014004537T5 (de) 2013-10-01 2016-07-21 Kymab Limited Tiermodelle und therapeutische Moleküle
JP6267986B2 (ja) * 2014-02-13 2018-01-24 株式会社特殊免疫研究所 ヒトの特定分子と結合する分子標的物質のｉｎｖｉｖｏ評価法
KR102276752B1 (ko) * 2014-03-21 2021-07-13 리제너론 파마슈티칼스 인코포레이티드 단일 도메인 결합 단백질을 생산하는 비-인간 동물
WO2015143406A2 (en) 2014-03-21 2015-09-24 Regeneron Pharmaceuticals, Inc. Vl antigen binding proteins exhibiting distinct binding characteristics
CA2959428A1 (en) 2014-09-19 2016-03-24 Regeneron Pharmaceuticals, Inc. Chimeric antigen receptors
EP3271403A1 (en) 2015-03-19 2018-01-24 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
TW202417497A (zh) 2015-10-12 2024-05-01 美商再生元醫藥公司 活化瘦素受體的抗原結合蛋白
AU2017206785C1 (en) 2016-01-13 2023-09-07 Regeneron Pharmaceuticals, Inc. Rodents having an engineered heavy chain diversity region
AU2017221425A1 (en) 2016-02-16 2018-08-23 Regeneron Pharmaceuticals, Inc. Non-human animals having a mutant kynureninase gene
IL323024A (en) * 2016-05-20 2025-10-01 Regeneron Pharma Methods for breaking immunological tolerance using multiple guide RNAs
HUE061619T2 (hu) 2016-06-03 2023-07-28 Regeneron Pharma Exogén terminális dezoxinukleotid-transzferázt expresszáló rágcsálók
WO2017214089A1 (en) 2016-06-06 2017-12-14 Regeneron Pharmaceuticals, Inc. Non-human animals expressing antibodies with human lambda light chains
WO2018128691A1 (en) 2016-11-04 2018-07-12 Regeneron Pharmaceuticals, Inc. Non-human animals having an engineered immunoglobulin lambda light chain locus
US11122042B1 (en) 2017-05-12 2021-09-14 F5 Networks, Inc. Methods for dynamically managing user access control and devices thereof
FI3635009T3 (fi) 2017-06-07 2026-04-07 Regeneron Pharma Koostumuksia ja menetelmiä entsyymien internalisoimiseksi
DK4140297T3 (da) 2017-12-05 2025-06-23 Regeneron Pharma Mus med en konstrueret immunglobulin-lambda-letkæde og anvendelser deraf
JP7779653B2 (ja) 2018-02-07 2025-12-03 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 治療用タンパク質送達のための方法および組成物
US20210000088A1 (en) 2018-03-21 2021-01-07 Crystal Bioscience Inc. Transgenic chicken that produces human antibodies
WO2019190922A1 (en) 2018-03-24 2019-10-03 Regeneron Pharmaceuticals, Inc. Genetically modified non-human animals for generating therapeutic antibodies against peptide-mhc complexes, methods of making and uses thereof
KR20250121150A (ko) 2018-03-26 2025-08-11 리제너론 파마슈티칼스 인코포레이티드 치료제를 시험하기 위한 인간화된 설치류
DK3773713T3 (da) 2018-04-06 2025-08-18 Regeneron Pharma Leptinreceptoragonistantistof til anvendelse i forøgelse af knoglemasse hos et individ, der lider af metabolisk dysfunktion eller hypoleptinæmI
EP3793591A1 (en) 2018-05-17 2021-03-24 Regeneron Pharmaceuticals, Inc. Anti-cd63 antibodies, conjugates, and uses thereof
US12102070B2 (en) 2018-06-13 2024-10-01 Crystal Bioscience Inc. Camelization of a human variable domain by gene conversion
IL318469A (en) 2018-06-14 2025-03-01 Regeneron Pharma Non-human animals capable of reorganizing transgenic DH-DH, and their uses
EP3927832A4 (en) 2019-02-18 2022-11-30 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. GENETICALLY MODIFIED NON-HUMAN ANIMALS WITH HUMANIZED IMMUNOGLOBULIN LOCUS
JP2022520819A (ja) 2019-02-22 2022-04-01 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 遺伝子改変ナトリウムチャネルを有する齧歯類およびその使用方法
SG11202111258TA (en) 2019-06-05 2021-11-29 Regeneron Pharma Non-human animals having a limited lambda light chain repertoire expressed from the kappa locus and uses thereof
DK3785536T4 (da) * 2019-08-28 2025-10-27 Trianni Inc Adam6-knockin-mus
JP7726881B2 (ja) 2019-12-02 2025-08-20 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ペプチド－ｍｈｃ ｉｉタンパク質構築物およびそれらの使用
KR20230018439A (ko) 2020-06-02 2023-02-07 바이오사이토젠 파마슈티컬스 (베이징) 컴퍼니 리미티드 공동 경쇄 면역글로불린 좌위를 갖는 유전자 변형 비인간 동물
CA3187680A1 (en) 2020-09-11 2022-03-17 Yashu Liu Identification and production of antigen-specific antibodies
WO2022132943A1 (en) 2020-12-16 2022-06-23 Regeneron Pharmaceuticals, Inc. Mice expressing humanized fc alpha receptors
CA3165366A1 (en) 2020-12-23 2022-06-30 Regeneron Pharmaceuticals, Inc. Nucleic acids encoding anchor modified antibodies and uses thereof
TW202242114A (zh) 2020-12-23 2022-11-01 美商再生元醫藥公司 用於獲得結合至跨膜蛋白之抗體以及抗體生成細胞的方法
EP4326765A1 (en) 2021-04-20 2024-02-28 Regeneron Pharmaceuticals, Inc. Human antibodies to artemin and methods of use thereof
MA71452A (fr) 2022-07-12 2025-04-30 Regeneron Pharmaceuticals, Inc. Anticorps dirigés contre le récepteur du facteur neurotrophique ciliaire (cntfr) et leurs procédés d'utilisation
KR20250150011A (ko) 2023-02-13 2025-10-17 리제너론 파마슈티칼스 인코포레이티드 항-인간 cacng1 항체를 이용한 근육 관련 장애 치료
EP4705343A1 (en) 2023-05-02 2026-03-11 Regeneron Pharmaceuticals, Inc. Anti-human m-cadherin (cdh15) antibodies, conjugates, and uses thereof for delivery of genetic payloads to muscle cells
WO2025014533A1 (en) 2023-07-10 2025-01-16 Regeneron Pharmaceuticals, Inc. Anti-human cacng1 antibody-drug conjugates and uses thereof
CN120035380A (zh) * 2023-09-15 2025-05-23 赛业（苏州）生物科技有限公司 用于制备抗体的基因修饰小鼠及其制备方法
WO2025055311A1 (zh) 2023-09-15 2025-03-20 赛业（苏州）生物科技有限公司 用于制备抗体的基因修饰小鼠及其制备方法
WO2025064738A1 (en) 2023-09-22 2025-03-27 Regeneron Pharmaceuticals, Inc. Dntt 250-258 off-target peptides and uses thereof
WO2025064761A1 (en) 2023-09-22 2025-03-27 Regeneron Pharmaceuticals, Inc. Kras10-18 g12d off-target peptides and uses thereof
CN118339300A (zh) * 2024-01-02 2024-07-12 江苏集萃药康生物科技股份有限公司 产生人源化抗体的动物模型及其构建方法
WO2026006724A1 (en) 2024-06-28 2026-01-02 Regeneron Pharmaceuticals, Inc. Prame off-target peptides and uses thereof
WO2026006734A1 (en) 2024-06-28 2026-01-02 Regeneron Pharmaceuticals, Inc. Off-target peptide-mhc complex conformation modeling systems and methods for antigen-recognition molecule development
WO2026030428A2 (en) 2024-08-01 2026-02-05 Regeneron Pharmaceuticals, Inc. Prostate-specific antigen peptides and uses thereof
WO2026035843A2 (en) 2024-08-06 2026-02-12 Regeneron Pharmaceuticals, Inc. Non-human animals having modified immunoglobulin heavy chain constant region locus and uses thereof

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
US6657103B1 (en) 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US7041871B1 (en) 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1994012215A1 (en) * 1992-12-01 1994-06-09 Protein Design Labs, Inc. Humanized antibodies reactive with l-selectin
EP1500329B1 (en) 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
CN1203922A (zh) * 1997-03-21 1999-01-06 三共株式会社 人源化抗人fas抗体
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
RU10506U1 (ru) 1999-04-08 1999-08-16 Кривулин Виталий Николаевич Ручной культиватор
WO2000073323A2 (en) * 1999-05-27 2000-12-07 Human Genome Sciences, Inc. Adam polynucleotides and polypeptides
GB0001448D0 (en) * 2000-01-21 2000-03-08 Novartis Ag Organic compounds
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7034134B2 (en) 2001-04-26 2006-04-25 Bristol-Myers Squibb Company Polynucleotide encoding a novel metalloprotease highly expressed in the testis, MMP-29
US7476536B2 (en) * 2001-05-11 2009-01-13 Kirin Pharma Kabushiki Kaisha Artificial human chromosome containing human antibody a light chain gene
US7473557B2 (en) 2001-06-06 2009-01-06 Regeneron Pharmaceuticals, Inc. Method for targeting transcriptionally active loci
US20060199204A1 (en) 2001-10-05 2006-09-07 U.S. Epa Genetic testing for male factor infertility
US20030108925A1 (en) 2001-10-05 2003-06-12 U.S. Epa Genetic testing for male factor infertility
JP4099646B2 (ja) 2002-06-04 2008-06-11 株式会社安川電機 ボイスコイルモータ
NZ537277A (en) 2002-07-18 2008-04-30 Crucell Holland Bv Recombinant production of mixtures of antibodies
RU2251699C1 (ru) * 2003-09-25 2005-05-10 Киселев Всеволод Иванович Способ ранней и доклинической диагностики цервикального рака
AU2005295269B2 (en) 2004-10-19 2010-05-13 Regeneron Pharmaceuticals, Inc. Method for generating an animal homozygous for a genetic modification
PL1739691T3 (pl) 2005-06-30 2009-06-30 Borealis Tech Oy Zewnętrzne osłony dla kabli elektroenergetycznych lub telekomunikacyjnych
AU2007235496B2 (en) 2006-03-31 2013-11-21 E. R. Squibb & Sons, L.L.C. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
ES2398076T3 (es) 2006-06-02 2013-03-13 Regeneron Pharmaceuticals, Inc. Anticuerpos de alta afinidad contra el receptor de IL-6 humano
WO2009097006A2 (en) 2007-08-10 2009-08-06 Medarex, Inc. Hco32 and hco27 and related examples
US7659842B2 (en) 2007-10-24 2010-02-09 Infineon Technologies Ag Quantization error reduction in PWM full-MASH converters
EP2346994B1 (en) 2008-09-30 2022-02-16 Ablexis, LLC Knock-in mice for the production of chimeric antibodies
JP5827127B2 (ja) * 2008-12-18 2015-12-02 エラスムス・ユニヴァーシティ・メディカル・センター・ロッテルダム ヒト化抗体を発現する非ヒトトランスジェニック動物及びその使用
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
JP5399140B2 (ja) * 2009-06-18 2014-01-29 株式会社タイトー モールス信号通信システム
BR112012000536A2 (pt) 2009-07-08 2020-08-11 Kymab Limited métodos para produção de anticorpo ou cadeia leve ou pesada de anticorpo específico para um antígeno desejado, para produção de anticorpo ou cadeia de anticorpo e seu uso, composição farmacêutica e derivado de anticorpo quimérico
US8754287B2 (en) * 2009-12-10 2014-06-17 Regeneron Pharmaceuticals, Inc. Mice that make heavy chain antibodies
SI2501817T2 (sl) 2010-02-08 2021-09-30 Regeneron Pharmaceuticals, Inc. Miš z navadno lahko verigo
US20120021409A1 (en) 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
AU2011266843C9 (en) 2010-06-17 2018-03-01 Kymab Limited Animal models and therapeutic molecules
RU2722373C2 (ru) 2011-02-25 2020-05-29 Редженерон Фармасьютикалс, Инк. Мыши adam6
RS59728B1 (sr) 2011-08-05 2020-02-28 Regeneron Pharma Humanizovani miševi univerzalnog lakog lanca
KR20160098514A (ko) 2011-10-17 2016-08-18 리제너론 파아마슈티컬스, 인크. 제한된 면역글로불린 중쇄 마우스
GB201118579D0 (en) 2011-10-27 2011-12-07 Micromass Ltd Control of ion populations
GB201122047D0 (en) 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
RU2664181C2 (ru) 2011-12-20 2018-08-15 Регенерон Фармасьютикалз, Инк. Мыши с гуманизированной легкой цепью
PT3597037T (pt) 2012-06-12 2021-06-01 Regeneron Pharma Animais não humanos humanizados com lócus de cadeia pesada de imunoglobulina restrito

Also Published As

Publication number Publication date
SMT201500061B (it) 2015-05-05
AU2015238806A1 (en) 2015-10-29
DE12716101T1 (de) 2013-05-08
AU2022206806A1 (en) 2022-08-18
EP2738258A3 (en) 2014-09-24
RU2013125717A (ru) 2014-12-10
HUE024534T2 (hu) 2016-01-28
US9944716B2 (en) 2018-04-17
CN103429746A (zh) 2013-12-04
SG10201913160QA (en) 2020-03-30
RS59413B1 (sr) 2019-11-29
EP4067496B1 (en) 2023-03-29
IL268671B (en) 2020-05-31
DK2578688T1 (da) 2014-11-24
HUE062552T2 (hu) 2023-11-28
DK2578688T4 (da) 2023-05-08
ES2805364T3 (es) 2021-02-11
CY1122205T1 (el) 2020-11-25
ZA201305998B (en) 2016-07-27
US10905109B2 (en) 2021-02-02
DE14154918T1 (de) 2014-08-21
JP2022071051A (ja) 2022-05-13
PT2738258T (pt) 2019-12-10
JP2025032218A (ja) 2025-03-11
AU2025283466A1 (en) 2026-01-22
EP3744850A1 (en) 2020-12-02
JP5866127B2 (ja) 2016-02-17
US10072095B2 (en) 2018-09-11
EP2738259B1 (en) 2019-11-27
SMT202000112T1 (it) 2020-05-08
DK2738259T1 (da) 2014-11-24
DE14176593T1 (de) 2015-03-05
SG10201405135RA (en) 2014-10-30
US20210105984A1 (en) 2021-04-15
SMT201900744T1 (it) 2020-01-14
BR112013021771A2 (pt) 2017-07-04
LT2738258T (lt) 2020-01-10
SI2578688T2 (sl) 2023-05-31
ES2758974T5 (es) 2023-06-08
DK2578688T3 (da) 2019-10-28
US20150201589A1 (en) 2015-07-23
EP2738258A2 (en) 2014-06-04
SI2578688T1 (sl) 2019-11-29
EP2738258B1 (en) 2019-09-25
NZ813867A (en) 2026-02-27
US20180346598A1 (en) 2018-12-06
FI2578688T4 (fi) 2023-05-05
PT4067496T (pt) 2023-06-07
PT2550363E (pt) 2015-03-16
DK2738258T3 (da) 2019-12-16
DK2738259T3 (da) 2020-02-17
IL273986A (en) 2020-05-31
CN105861548A (zh) 2016-08-17
US10694725B2 (en) 2020-06-30
RS59929B1 (sr) 2020-03-31
HRP20200294T1 (hr) 2020-05-29
ES2532487T3 (es) 2015-03-27
FI4067496T3 (fi) 2023-05-24
CY1116301T1 (el) 2017-02-08
IL268671A (en) 2019-10-31
PL4067496T3 (pl) 2023-07-31
SMT201900581T1 (it) 2019-11-13
AU2020201279A1 (en) 2020-03-12
DK2813573T1 (da) 2015-01-12
LT2578688T (lt) 2019-11-11
SMT202300173T1 (it) 2023-07-20
MX375115B (es) 2025-03-06
RS53880B1 (sr) 2015-08-31
US20120322108A1 (en) 2012-12-20
MX2020009714A (es) 2020-10-07
PL2738259T3 (pl) 2020-08-24
NZ612643A (en) 2015-06-26
US8642835B2 (en) 2014-02-04
MX343009B (es) 2016-10-21
PL2578688T5 (pl) 2023-05-29
ES2748832T3 (es) 2020-03-18
US20140213773A1 (en) 2014-07-31
JP2018143250A (ja) 2018-09-20
US12207628B2 (en) 2025-01-28
DK4067496T5 (da) 2024-07-22
ES2946169T3 (es) 2023-07-13
BR112013021771B1 (pt) 2022-11-16
DK2550363T3 (en) 2015-03-23
LT2738259T (lt) 2020-03-10
US20180346599A1 (en) 2018-12-06
DE12192727T1 (de) 2013-07-11
JP2014110814A (ja) 2014-06-19
PL2578688T3 (pl) 2020-05-18
KR20130116375A (ko) 2013-10-23
SG10201913155QA (en) 2020-02-27
HRP20191895T1 (hr) 2020-01-10
RU2722373C2 (ru) 2020-05-29
LT4067496T (lt) 2023-06-12
ME02106B (me) 2015-10-20
SI2738259T1 (sl) 2020-06-30
SI2738258T2 (sl) 2023-05-31
DK2738258T4 (da) 2023-05-08
RU2016109443A3 (https=) 2019-07-24
RS59413B2 (sr) 2023-06-30
PL2738258T5 (pl) 2023-05-15
SI2550363T1 (sl) 2015-04-30
KR101387377B1 (ko) 2014-04-21
AU2017251802A1 (en) 2017-11-16
US20180362663A1 (en) 2018-12-20
CN103429746B (zh) 2016-05-11
AU2022206806B2 (en) 2025-10-02
US20240306617A1 (en) 2024-09-19
NZ703609A (en) 2016-04-29
PL2550363T3 (pl) 2015-05-29
CY1122820T1 (el) 2021-05-05
EP4067496A1 (en) 2022-10-05
ES2758974T3 (es) 2020-05-07
HUE046081T2 (hu) 2020-01-28
NZ718688A (en) 2017-07-28
US10905108B2 (en) 2021-02-02
HK1201292A1 (en) 2015-08-28
HRP20192311T4 (hr) 2023-05-12
SI4067496T1 (sl) 2023-07-31
IL261243A (en) 2018-10-31
US9932408B2 (en) 2018-04-03
MY172713A (en) 2019-12-11
US20150210776A1 (en) 2015-07-30
EP2578688B1 (en) 2019-07-24
ES2770424T3 (es) 2020-07-01
HRP20192311T1 (hr) 2020-03-20
CY1126091T1 (el) 2023-11-15
DK4067496T3 (da) 2023-06-26
EP2550363B1 (en) 2014-12-10
ME03537B (https=) 2020-04-20
RS64280B1 (sr) 2023-07-31
RS59661B1 (sr) 2020-01-31
US20180345760A1 (en) 2018-12-06
US20130254911A1 (en) 2013-09-26
PL2738258T3 (pl) 2020-08-24
EP2550363A1 (en) 2013-01-30
ME03732B (me) 2021-01-20
JP2014507137A (ja) 2014-03-27
EP2738259A3 (en) 2014-07-30
AU2012243291A1 (en) 2013-05-09
PT2578688T (pt) 2019-10-24
US11950578B2 (en) 2024-04-09
JP2015107131A (ja) 2015-06-11
IN2013CN07629A (https=) 2015-08-07
PT2738259T (pt) 2020-02-18
AU2012243291B2 (en) 2015-07-09
SI2738258T1 (sl) 2020-01-31
US20210105985A1 (en) 2021-04-15
CY1122459T1 (el) 2021-01-27
RU2016109443A (ru) 2018-11-26
US10577430B2 (en) 2020-03-03
ES2748832T5 (es) 2023-06-08
HRP20230526T1 (hr) 2023-09-01
DE14154967T1 (de) 2014-08-28
IL273986B (en) 2021-04-29
SG192933A1 (en) 2013-09-30
HUE046746T2 (hu) 2020-03-30
NZ731926A (en) 2021-07-30
JP2019187446A (ja) 2019-10-31
EP2813573B1 (en) 2020-04-22
HUE047687T2 (hu) 2020-05-28
IL226727A (en) 2016-08-31
HRP20150262T1 (hr) 2015-04-10
JP2016135143A (ja) 2016-07-28
CA2820824A1 (en) 2012-10-18
DK2738258T1 (da) 2014-11-24
MX2013009649A (es) 2013-09-26
IL261243B (en) 2019-08-29
EP2578688A1 (en) 2013-04-10
EP2813573A1 (en) 2014-12-17
EP2578688B2 (en) 2023-02-08
RU2582261C2 (ru) 2016-04-20
FI2738258T4 (fi) 2023-05-05
EP2738258B2 (en) 2023-02-01
RS59661B2 (sr) 2023-06-30
CN105861548B (zh) 2020-01-10
NZ776770A (en) 2023-03-31
HK1174490A1 (en) 2013-06-14
WO2012141798A1 (en) 2012-10-18
US8697940B2 (en) 2014-04-15
EP2738259A2 (en) 2014-06-04
NZ797720A (en) 2024-09-27

Similar Documents

Publication Publication Date Title
HRP20191895T4 (hr) Adam6 miševi
FI4082334T3 (fi) Muokatun immunoglobuliinin lambda-kevytketjun lokuksen omaavia ei-humaaneja eläimiä
BR112014008775A8 (pt) Métodos para produzir camundongos com locus restrito de cadeia pesada de imunoglobulina, para obter célula ou tecido de camundongos, para produzir sequência de ácido nucleico que codifica domínio variável de cadeia pesada humano, bem como ácido nucleico
MX2020010837A (es) Ratones que expresan un repertorio limitado de cadena ligera de inmunoglobulina.
MX2021000286A (es) Raton de cadena ligera comun.
MY185881A (en) Non-human animals with modified immunoglobulin heavy chain sequences
MX379533B (es) Ratones de cadena ligera universal humanizados.
BR112016021572A2 (pt) Métodos para preparar um animal não humano geneticamente modificado e para produzir proteínas de ligação, hibridoma, ácido nucleico, célula, e, proteína de ligação
FI4233537T3 (fi) Humanisoituja m-csf-hiiriä ja niiden käyttötapoja
PH12016500342A1 (en) Non-human animals having a humanized signal-regulatory protein gene
MX388739B (es) Casetes optimizados de expresión del gen humano del factor viii de coagulación y su uso.
NZ707198A (en) Mice expressing a light chain with human lambda variable and mouse constant regions
BR112016015424A2 (pt) planta transgênica; polinucleotídeo recombinante; vetor de expressão expressável em plantas; método para a produção de uma planta transformada tendo fotossíntese aprimorada; e proteína quimérica
CL2013002068A1 (es) Linea celular de ratón con genes inactivados nav1.7 global viable; metodo para generar ratón con dichos genes inactivados; hibridoma.
BR112014018843A8 (pt) métodos para obter um animal não humano, para produzir uma protéina e para modificar um locus de cadeia pesada de imunoglobulina de um roedor, e, hibridoma
HRP20181892T4 (hr) Transgeni miševi
NZ604057A (en) Plant cytochrome p450
BR112015030105A2 (pt) Construção de gene quimérico, vetor recombinante, usos dos mesmos, bem como método para a produção de uma planta monocotiledônea com maior rendimento em comparação com uma planta monocotiledônea do tipo selvagem correspondente
HRP20210031T1 (hr) Pripravci i metode mutantskog faktora viii
MX383218B (es) Proteínas antiporter de protones/azúcar tonoplastidarias y su uso para incrementar la concentración de sacarosa en un organo vegetal acopiador de sacarosa.
BR112017012389A2 (pt) supressão de rnai parental de gene kruppel para controlar pragas de coleóptero
AR088321A1 (es) Gen codificador de citocromo p450 y su uso
AR109237A1 (es) Anticuerpos contra ip-10 y sus usos
ECSP24018648A (es) Promotor inducible, vector y célula huésped basados en el mismo
TH166794A (th) สัตว์ที่ไม่ใช่มนุษย์ที่เป็นแบบฮิมแมไนซ์ที่มีโลคัสที่จำกัดของสายหนักของอิมมูโนโกลบูลิน